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The single application of high-concentration of capsaicin has been used as an analgesic therapy of persistent pain.
However, its effectiveness and underlying mechanisms remain to be further evaluated with experimental approaches.
The present study provided evidence showing that the single application of capsaicin dose-dependently alleviated
nociceptive hypersensitivity, and reduced the action potential firing in small-diameter neurons of the dorsal root
ganglia (DRG) in rats and mice. Pre-treatment with capsaicin reduced formalin-induced acute nocifensive behavior after
a brief hyperalgesia in rats and mice. The inhibitory effects of capsaicin were calcium-dependent, and mediated by the
capsaicin receptor (transient receptor potential vanilloid type-1). We further found that capsaicin exerted inhibitory
effects on the persistent nociceptive hypersensitivity induced by peripheral inflammation and nerve injury. Thus, these
results support the long-lasting and inhibitory effects of topical capsaicin on persistent pain, and the clinic use of
capsaicin as a pain therapy.Background
Topical application of capsaicin has long been clinically
used to treat persistent pain, such as osteoarthritic pain,
post-herpetic neuralgia of the trigeminal nerve, migraine
prophylaxis, diabetic neuropathy, HIV-associated distal
sensory neuropathy, and intractable pain in cancer pa-
tients [1-9]. Capsaicin is an agonist of transient receptor
potential cation channel, subfamily V, member 1 (TRPV1),
which is expressed in small-diameter neurons of the dor-
sal root ganglion (DRG) [10]. Topical treatment with cap-
saicin in human initially results in nociceptor firing and a
period of enhanced sensitivity to painful heat stimuli, and
then a refractory period during which resistant to cap-
saicin and heat but not pinprick stimuli [4,11-14].
Application of capsaicin can induce long-lasting ther-
mal hypoalgesia in the inflammatory model [15], and
another TRPV1 agonist resiniferatoxin (RTX) allevi-
ates the thermal nociception in the physiological state
and under the inflammatory condition [16].* Correspondence: xu.zhang@ion.ac.cn
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unless otherwise stated.Neuronal TRPV1 is a homotetrameric, nonselective
ligand-gated cation channel which can be activated by a
wide range of stimuli, including heat, proton, exogenous
compounds such as capsaicin and endovanilloids [17-19].
Studies with the TRPV1 gene knockout mice show that
TRPV1 is involved in the nociceptive response induced by
noxious heat (>50°C) and inflammation-induced thermal
hyperalgesia, although responsiveness to noxious heat
stimuli is not completely lost in TRPV1-deficient mice
[20-22]. Capsaicin opens TRPV1 channel not only to in-
crease the intracellular level of calcium and induce mem-
brane depolarization, but also to initiate the desensitization
and downregulation of TRPV1, and the degeneration of
epidermal nerve fibers, which is referred as defunctionali-
zation following continuous capsaicin exposure [5,23-26].
The long refractory period of the neurons which were
excited previously by capsaicin may result from calcium-
dependent conformational changes in TRPV1 protein, ul-
timately closing the channel pore [27]. However, this effect
was presumably temporary and therefore might not ac-
count for a persistent pain relief observed clinically.
Studies on the mechanisms for long-lasting analgesia
after continuous application of capsaicin suggest that the
capsaicin treatment leads to the dysfunctionalization of
TRPV1-containing nerve terminals in the skin and periph-
eral tissues, due to the long-term, functional and pheno-
typic alternation of neurons [26,28-31]. Capsaicin inhibitss is an Open Access article distributed under the terms of the Creative
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capsaicin-sensitive DRG neurons, and repeated applica-
tion of capsaicin produced membrane depolarization
but failed to evoke action potentials [27,32-34]. Re-
peated treatment with capsaicin may reversibly de-
crease the density of epidermal nerve fibers, and
thus the nociceptive deficiency could be induced
several days after treatment and may last for weeks
[4,5,24,26,29,35-38].
Recent clinical practice and study show that a single
60-min or 30-min application of 8% capsaicin patch
was found to provide significant pain relief for at least
12 weeks in patients suffering persistent pain including
peripheral neuropathic pain [30,31,39-43]. However,
the experimental evidence for such an application of
capsaicin remains to be obtained to evaluate its effect-
iveness and potential mechanisms for treatment of acute
and chronic pain.
The present study showed that after a brief excitatory
effect on capsaicin-sensitive DRG neurons and a transi-
ent nociceptive response of rats, a single application of
capsaicin inhibited the action potential (AP) firing in
capsaicin-sensitive DRG neurons and alleviated the
nociceptive hypersensitivity in the acute pain model in-
duced by formalin, the inflammatory pain model by
complete Freund’s adjuvant (CFA) and neuropathic pain
model by spared nerve injury (SNI). This inhibitory ef-
fect of capsaicin was mediated by TRPV1 channel, and
appeared to be dependent on the dosage of capsaicin
and calcium influx. These results provide a line of ex-
perimental evidence of the long-lasting and inhibitory
effects of topical capsaicin on persistent pain, and sup-
port the clinic use of capsaicin as a pain therapy.
Results
Capsaicin pretreatment induces analgesic effect on the
formalin-induced nociceptive response
We firstly examined the effect of capsaicin on the acute
nociceptive response induced by intraplantar injection
of formalin. As expected, the rats developed nocifen-
sive behavior after receiving the capsaicin (25, 50 and
100 μg) injection at the hindpaw, as compared to the
rats received the vehicle injection (Figure 1A). The
flinch number of the hindpaw was increased to a peak
level 10 min after the injection of 25, 50 and 100 μg
capsaicin, and then gradually decreased 20–60 min
after the capsaicin injection (Figure 1A). Most time
points between vehicle group and capsaicin group
showed significant difference (10, 20, 30, 40, 60 and
70 min between vehicle group and 25 μg group; 10, 20,
30, 40, 50 and 70 min between vehicle group and 50 μg
group; 10, 30, 40, 50 and 60 min between vehicle group
and 100 μg group). The increased flinch behavior dis-
appeared 90 min after capsaicin injection.Formalin injection caused a stereotypic two-phase
pattern of nociceptive response shown by the increase
in flinch number of the hindpaw. The phase I oc-
curred within 0–10 min due to periphery nociceptive
response, and the phase II appeared winthin 10–
60 min due to central nociceptive reaction (Figure 1B).
To examine the effect of capsaicin on acute pain, cap-
saicin (50 μg or 100 μg) was intraplantarly injected
into the hindpaw 120 min before the formalin injec-
tion (Figure 1B). The formalin-induced nociceptive re-
sponse in the phase I and phase II were both inhibited
by the pretreatment with 100 μg capsaicin but not
50 μg capsaicin (Figure 1B), suggesting that the capsa-
icin pretreatment could dose-dependently prevent the
formalin-induced acute nociceptive hypersensitivity.
Similar to the rats, the formalin-induced nociceptive
response in mice could be inhibited by the pretreat-
ment with 10 μg capsaicin (Figure 1C).
Capsaicin suppresses the excitability of small DRG
neurons
To further examine whether the excitability of DRG
neuron was regulated by capsaicin, we performed
whole-cell patch-clamp recording in small neurons dis-
sociated from the rat DRGs. The action potentials initi-
ated by single current ramp stimulation were recorded
before 30 s capsaicin treatment, during the treatment
and 5 min washout after the treatment, respectively
(Figure 2A). The TRPV1-positive neuron was recog-
nized once an inward current was induced after puffing
capsaicin. The action potential frequency in small DRG
neurons was increased transitorily in response to the
treatment with 2 μM capsaicin (Figure 2A and B), con-
sistent with the acute nociceptive behavior following
capsaicin treatment.
However, after washout with the extracellular solution
(ECS) for 5 min, the same neurons no longer fired the
action potentials in response to the same current ramp
stimulation (Figure 2A and B). Furthermore, we found
that this effect was dose-dependent, because 0.25 μM
and 0.5 μM of capsaicin reduced the action potential
frequency after 5 min washout to 0.25 (0.25 ± 0.07)-fold
and 0.18 (0.18 ± 0.13)-fold of that before capsaicin treat-
ment, respectively, while 2 μM of capsaicin completely
suppressed the action potential firing (Figure 2C). At
the same time interval, the membrane potential of the
capsaicin-stimulated neurons returned to the basal
levels, and the second treatment with 2 μM capsaicin
could induce inward current with ~48% of the ampli-
tude of first one (n = 5). Taken together, the treatment
with capsaicin could result in a dose-dependent inhibi-
tory effect on the excitability of small DRG neurons,
consistent with the reduction in the nocicptive behavior
after capsaicin pretreatment observed in rats.
Figure 1 Capsaicin treatment causes acute algetic responses and a subsequent analgesic effect. (A) Time course of 90 min following intraplantar injection
of 25 (n = 9 rats), 50 (n = 16) and 100 μg (n = 12) capsaicin or vehicle (n = 14) (p < 0.001 for 25 μg, p < 0.001 for 50 μg and p< 0.001 for 100 μg capsaicin
versus vehicle control group, ANOVA). The quantitative analysis showed that the number of flinches was increased at capsaicin-injected hindpaw. (B)
Intraplantar pre-injection of 100 μg capsaicin (n = 13) but not 50 μg capsaicin (n = 8) or vehicle (n = 12) induced an analgesic effect in the pain model
induced by 2% formalin (p < 0.001 for 100 μg capsaicin versus vehicle group, ANOVA). The time course showed that the inhibitory effect of capsaicin on
the formalin-induced flinch in the phase II was lasted for 30 min. The number of flinches in the phase I and phase II was reduced in the rats with capsaicin
pre-treatment. (C) Intraplantar pre-injection of 10 μg capsaicin (n = 15) reduced the licking time of mice induced by 2% formalin, compared to vehicle
group (n = 15) (p < 0.001, ANOVA). The licking time in both phase I and phase II was decreased in mice. Data are shown as mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001, versus vehicle group.
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To examine whether this capsaicin-induced inhibition
was specifically mediated via TRPV1, neurons dissoci-
ated from the rat DRGs were incubated with capsaze-
pine, the antagonist of TRPV1, for 30 min before the
treatment with 2 μM capsaicin. This pre-blockade of
TRPV1 prevented the capsaicin-induced reduction inthe action potential frequency after 5 min washout in
small DRG neurons (Figure 3A). Furthermore, we per-
formed whole-cell patch-clamp recording in small
DRG neurons dissociated from the DRGs of TRPV1
gene knock-out (TRPV1−/−) and wild-type littermate
(TRPV1+/+) mice. The 30 s pretreatment with 2 μM
capsaicin and following 5 min washout in the
Figure 2 Pre-treatment with capsaicin reduces the excitability of small DRG neurons of rats. (A) Whole-cell patch-clamp recording in small
neurons acutely dissociated from the rat DRGs showed that the firing frequency of action potentials induced by a current ramp (1 s duration;
peak ranging from 100–500 pA) was firstly increased, and was then decreased after 5 min washout of capsaicin. (B) The action potential
frequency during capsaicin treatment was increased to 3.12 (3.12 ± 0.65)-folds of that recorded before treatment, and such a change was
attenuated in the same neuron after 5 min washout. **p < 0.01, ***p < 0.001, versus the same group of neurons before capsaicin treatment
(n = 15 neurons). (C) The capsaicin-induced suppression of action potential was dose-dependent. The action potential frequency after
5 min washout reduced to 0.25-fold and 0.18-fold of that before 0.25 μM (n = 26) and 0.5 μM (n = 9) capsaicin treatment, respectively, and
was almost totally suppressed with 2 μM capsaicin (n = 11).
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TRPV1+/+ mice reduced the action potential frequency
to 0.08 (0.08 ± 0.08)-fold of that before capsaicin
treatment, while the capsaicin-insensitive neurons had
no obvious changes (Figure 3B and C). In contrast, the
small DRG neurons (n = 31) from TRPV1−/− mice did
not show any changes in the action potential fre-
quency (Figure 3B and C). We also examined the
effect of capsaicin at a higher concentration. The 30 s
pretreatment with 1 mM capsaicin and following
5 min washout reduced the action potential frequency
to 0.02 (0.02 ± 0.02)-fold of that before capsaicin
treatment in the capsaicin-sensitive small neurons
(n = 8/22) from TRPV1+/+ mice, while the capsaicin-
insensitive neurons from wild-type mice and the
small DRG neurons (n = 10) from TRPV1−/− mice
did not show any changes in the action potential fre-
quency (Figure 3D). Thus, TRPV1 in small DRG
neurons is required for the capsaicin-induced inhib-
ition of excitability.
We further examined the effect of capsaicin on the
formalin-induced nociceptive response in TRPV1−/−
mice. The capsaicin-induced inhibition on the phase I
and phase II of the formalin-induced nociceptive re-
sponse was lost in TRPV1−/− mice (Figure 3E). Thesedata suggest that TRPV1 is required for the capsaicin-
induced inhibition.
Capsaicin-induced inhibition is calcium-dependent
Considering TRPV1 as a non-selective cation channel, we
next asked whether calcium influx induced by activation of
TRPV1 was involved in the capsaicin-induced analgesia.
Small DRG neurons dissociated from rats were incubated
in the calcium-free ECS, and were then stimulated by a
current ramp. We found that in the absence of extra-
cellular calcium, 2 μM capsaicin treatment reduced
the action potential frequency after 5 min washout to
0.66 (0.66 ± 0.07)-fold of that before capsaicin treat-
ment (Figure 4A). This result suggests that the influx
of extracellular calcium is required for the capsaicin-
induced inhibition on nociceptive afferent neurons.
To test whether the extracellular calcium affect
the capsaicin-induced analgesia, 50 μg capsaicin was
mixed with 10 mM calcium was injected 120 min
before formalin injection. This mixture significantly
reduced the nociceptive response in the phase II of
formalin test and also caused a tendency of de-
creased response in the phase I, whereas 50 μg cap-
saicin and 10 mM calcium alone did not affect the
nociceptive response (Figure 4B and C). Taken
Figure 3 TRPV1 is required for the inhibitory effect of capsaicin on the neuronal excitability and formalin-induced nociceptive response. (A)
Treatment with TRPV1 antagonist, capsazepine, attenuated the capsaicin-induced reduction in action potential frequency in small DRG
neurons (n = 13). (B, C, D) Whole-cell patch-clamp recording showed that the capsaicin-induced reduction of action potential frequency in
capsaicin-sensitive small DRG neurons (for 2 μM capsaicin, 10 positive neurons out of 34; for 1 mM capsaicin, 8 positive neurons out of 22)
dissociated from TRPV1+/+ littermates was absent in small DRG neurons from TRPV1−/− mice (for 2 μM capsaicin, n = 31; for 1 mM capsaicin,
n = 10). (E) The licking time in both phase I and phase II of mice induced by 2% formalin was not affected by intraplantar pre-injection of
10 μg capsaicin (n = 8), compared to vehicle group (n = 8). Data are shown as mean ± SEM.
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ceptive response could be regulated by the influx of
extracellular calcium.
Capsaicin reduces the nociceptive hypersensitivity
induced by peripheral inflammation and nerve injury
Using chronic inflammatory pain model induced by
CFA and the neuropathic pain model induced by SNI,
we evaluated whether capsaicin could alleviate persist-
ent mechanical allodynia. The von Frey test was used
to measure the mechanical threshold of rats. The
mechanical allodynia developed 2 days after intraplan-
tar injection of CFA at left hindpaw. We found that the
intraplantar injection of 50 μg capsaicin reduced
mechanical allodynia in subsequent 2 h compared tothe vehicle-injected control group, while the analgesic
effect of 100 μg capsaicin lasted for at least 24 h
(Figure 5A). Furthermore, small DRG neurons dissociated
from the CFA-treated rats were recorded to examine the
neuronal excitability. A ramp current was injected into the
neuron to induce action potential before and after the cap-
saicin application. After puffing 2 μM capsaicin for 30 s,
the action potential frequency was completely suppressed
after 5 min washout (Figure 5B).
We also evaluated the effect of capsaicin treatment
on the mechanical allodynia in the SNI model. Seven
days after SNI, the intraplantar injection of 100 μg cap-
saicin could mildly reduce the mechanical allodynia
(Figure 5C). Whole-cell patch-clamp recording showed
that in small DRG neurons dissociated from rats on
Figure 4 Calcium is involved in the capsaicin-induced inhibition on neuronal excitability and analgesia. (A) whole-cell patch-clamp recording
showed that in the absence of extracellular calcium, the ratio of action potential frequency was only partially inhibited in capsaicin-pretreated
small DRG neurons. ***p < 0.001, versus the same group of neurons before capsaicin treatment (n = 30). (B, C) Behavior test showed that 50 μg
capsaicin or 10 mM calcium or vehicle (n = 9) alone could not reduce the nociceptive response in the phase II of formalin test. However, the
injection of a mixture of 50 μg capsaicin with 10 mM calcium (n = 7) could inhibit the reaction in the phase II (p < 0.001 for rats treated with
capsaicin mixed with 10 mM calcium versus vehicle group, ANOVA). Data are shown as mean ± SEM. **p < 0.01, versus vehicle group.
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pletely suppressed the action potential frequency after
5 min washout (Figure 5D). Taken together, capsaicin
treatment alleviates the persistent nociceptive hyper-
sensitivity induced by peripheral inflammation and
nerve injury.
Discussion
The present study showed that a brief and topical cap-
saicin treatment could lead to long-lasting inhibition of
neuronal excitability in a dose- and calcium-dependent
manner, and alleviation of both acute and persistent
nociceptive responses. These results suggest that a sin-
gle application of capsaicin could produce a therapeutic
approach to effectively treat persistent pain.
Clinical practice suggests that capsaicin can be used
as an analgesic to relief pain [1-9]. Particularly, recent
reports show that a single 60-min or 30-min applicationof 8% capsaicin patch significantly relieves pain for
many weeks in patients [30,31,39-43]. However, the ex-
perimental evidence for the capsaicin-induced analgesia
and the related mechanism has been insufficient to sup-
port this clinical application of capsaicin. In the present
study, we analyzed the analgesic effect of capsaicin in
the animal models of acute and chronic pain, including
the formalin test, CFA model of chronic inflammatory
pain and SNI model of chronic neuropathic pain. Our
results showed that a single application of capsaicin
reduced the nociceptive hypersensitivity induced by
acute noxious stimulation and peripheral inflammation
or nerve injury. Notably, the analgesic effect of capsaicin
was more pronounced in the inflammation model than
that in the neuropathic pain model, which may be due
to the elevated expression of TRPV1 in inflammatory
condition and the reduced expression of TRPV1 in neuro-
pathic pain model [44,45]. Thus, the single injection of
Figure 5 Capsaicin alleviates the nociceptive hypersensitivity induced by peripheral inflammation or nerve injury. (A) Intraplantar injection of
100 μg capsaicin could reduce the mechanical allodynia 2 days after CFA injection (n = 12 for vehicle, n = 9 for 50 μg capsaicin treatment and
n = 11 for 100 μg capsaicin treatment). The significant analgesic effect of 100 μg capsaicin began 2 h after capsaicin injection and maintained
for 24 h, while 50 μg showed a shorter analgesic effect (p < 0.05 for 50 μg and p < 0.001 for 100 μg capsaicin versus vehicle group, ANOVA).
(B) Whole-cell patch-clamp recording showed that puffing 2 μM capsaicin for 30 s, the action potential frequency was totally suppressed after
5 min washout in small DRG neurons dissociated from rats injected CFA for 2 days. ***p < 0.001, versus the same group of neurons before
capsaicin treatment (n = 11). (C) Intraplantar injection of 100 μg capsaicin could mildly reduce mechanical allodynia 7 days after SNI (n = 8 for
vehicle and n = 9 for capsaicin treatment) (p < 0.01 for 100 μg capsaicin versus vehicle group, ANOVA). (D) Whole-cell patch-clamp recording
showed that treatment with 2 μM capsaicin for 30 s almost totally suppressed the action potential firing after 5 min washout in small DRG
neurons dissociated from rats on post-SNI day 7. ***p < 0.001, versus the same group of neurons before capsaicin treatment (n = 17). Data are
shown as mean ± SEM.
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tory pain than neuropathic pain.
Previous studies showed that capsaicin desensitizes
capsaicin-sensitive nociceptors by inhibiting the gener-
ation of action potentials through the indirect block
of voltage-gated sodium channels [27,32-34]. In the
present study, we found that a brief treatment with cap-
saicin could induce long-lasting suppressive effects on
the generation of action potentials in capsaicin-sensitive
DRG neurons in a dose- and calcium-dependent man-
ner, consistent with the inhibitory effects of a single
capsaicin treatment on the acute and persistent noci-
ceptive hypersensitivity. Our finding that high-dose
capsaicin produced more pronounced inhibition is
consistent with the clinical observation that high-
concentration topical capsaicin is required to treat
neuropathic pain [30,31,39,40,43,46]. Our present re-
sults show that the capsaicin-induced calcium influx in-
volves the acute regulation of both neuronal excitability
and nociceptive behavior induced by a single injection
of capsaicin. This is consistent with the notion that thelong refractory period of the neurons after capsaicin
treatment may result from calcium-dependent conform-
ational changes in TRPV1 protein [27], suggesting that
the refractory period of capsaicin-sensitive neurons also
accounts for the relief of persistent pain.
The refractory period of capsaicin-sensitive neurons
could be attributed to a desensitization state of TRPV1
or the depolarized state of DRG neuron after TRPV1
opening [2,42]. The present electrophysiological exper-
iments showed that there were a short period of
TRPV1 desensitization and membrane depolarization
following capsaicin treatment. However, after 5 min
washout, DRG neurons were re-sensitized to capsaicin
and the membrane potential returned to the basal
levels, whereas the neuronal excitability at the same
time interval was suppressed. Therefore, the analgesia
induced by a single application of capsaicin might be
not attributed to the TRPV1 desensitization or the
membrane depolarization of sensory neurons. An al-
ternative explanation could be a reduced excitability of
primary sensory neurons. Capsaicin was found to
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gated sodium channels in the DRG neurons that were
previously excited by capsaicin [27,32-34]. Moreover,
capsaicin induces sodium influx, which would indir-
ectly induce the membrane depolarization and inacti-
vation of voltage-gated sodium channels [32-34].
Therefore, a single application of capsaicin may
desensitize nociceptors by inhibiting the generation of
action potentials.
Previous studies showed that heat responses, but
not mechanical hyperalgesia or allodynia, were atten-
uated by ablation of TRPV1-lineage neurons using
genetic approach in mice [47]. TRPV1 may distribute
in both peptidergic and non-peptidergic neurons of
rats [48]. Selective blocking sodium channels in the
TRPV1-expressing neurons of rats showed reduced
response to both noxious mechanical and thermal
stimuli [49]. We found that intraplantar injection of
capsaicin attenuated mechanical hyperalgesia in the
CFA model and mechanical allodynia in SNI model
of the rat. One explanation is that high-dose capsa-
icin activated TRPV1 and then indirectly suppressed
the sodium channels in nociceptive afferent neurons
to reduce mechanical hypersensitivity.
Taken together, the present study showed that the
generation of action potentials was attenuated in the
capsaicin-sensitive DRG neurons that were previously
excited by a single and brief treatment of capsaicin. A
single injection of capsaicin significantly reduced the
nociceptive hypersensitivity in both the rat model of
peripheral inflammation and the model of neuropathic
pain. However, its effect on the inflammatory nocicep-
tive response is more pronounced than that in the
neuropathic pain model. Thus, our study provides ex-
perimental evidence supporting the single application




All experiments were approved by the Committee of
Use of Laboratory Animals and Common Facility, In-
stitute of Neuroscience, Chinese Academy of Sciences
and carried out according to the guidelines of the
International Association for the Study of Pain. All
animals were housed under a 12-h light/dark cycle at
22-26°C, with free access to food and water. Sprague–
Dawley male rats were bought from Shanghai SLAC
Laboratory Animal CO. LTD (SLAC). TRPV1 knock-
out (TRPV1−/−) mice were bought from the Jackson
Laboratory (JAX). The strain name is B6.129X1-
TRPV1tm1jul/J and the stock number is 003770. An
exon encoding part of the fifth and all of the sixth
putative trans-membrane domains together with thepore-loop region was disrupted [20]. The heterozy-
gotes were bred to obtain TRPV1−/− mice and their
wild-type littermates (TRPV1+/+). TRPV1−/− mice were
viable and fertile. Capsaicin and capsazepine were pur-
chased from Tocris Bioscience.
Animal models and behavior tests
For acute nociceptive response of capsaicin, rats were
divided into several groups after habituated in Perspex
chamber with a wire mesh floor for at least 2 h, ob-
served in the chamber, and then injected with vehicle
or different dose of capsaicin intraplantarly. The num-
ber of flinches was counted every 10 min during
90 min after injection.
For tonic inflammatory formalin test, rats were ha-
bituated in Perspex chamber for at least 2 h. The rats
were intraplantarly pretreated with vehicle or capsaicin
for 2 h. After that, 50 μl of 2% formalin (Sigma-
Aldrich) in saline was injected into the rat left hindpaw
intraplantarly. The number of flinches was counted
based on the first phase (1–10 min) and the second
phase (10–60 min) [50,51].
For formalin test in TRPV1+/+ and TRPV1−/− mice,
the mice were intraplantarly pretreated with vehicle or
10 μg capsaicin for 2 h. Then, mice were injected with
20 μl of 2% formalin into the dorsal surface of the left
hindpaw. The time that mice licked the injected paw
was recorded during the phase I (1–10 min) and II
(10–40 min).
As chronic inflammatory pain model, rats were
injected with 100 μl CFA (Sigma-Aldrich) at the hind-
paw intraplantarly. To determine the threshold for
mechanical pain response, the von Frey test was per-
formed 2 days after injection. For electrophysiological
experiment, CFA-treated rats were sacrificed 2 days
after injection.
As chronic neuropathic pain model, the SNI model
was performed on Sprague–Dawley rats as previously
described. Two of the three branches of the sciatic
nerve (common peroneal nerve and tibial nerve) were
injured, leaving the remaining sural nerve intact
[52,53]. The von Frey test and electrophysiological ex-
periment were performed on 7 d after SNI surgery.
To measure mechanical threshold, the rats were ha-
bituated in Perspex chamber for more than 2 h before
tests, and then graded von Frey filaments were applied
to the lateral area of the hindpaw, using the up-and-
down testing paradigm [54]. The minimum bending
force with three positive responses out of five stimuli
with von Frey filaments presented perpendicular to the
plantar surface of the rat hindpaw was determined as
the mechanical threshold.
All behavioral tests were all performed double-
blindly.
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L4 and L5 DRGs were acutely dissected from approxi-
mately 100 g Sprague–Dawley rats or approximately 20 g
TRPV1+/+ and TRPV1−/− mice after they were anesthetized
by injection of pentobarbital sodium (80 mg/kg). The con-
nective tissue was digested by 0.4 mg/ml trypsin type I
(Sigma-Aldrich), 1 mg/ml collagenase type 1A (Sigma-Al-
drich), and 0.1 mg/ml DNase I (Sigma-Aldrich) in DMEM
Medium (Gibco-Invitrogen, Carlsbad, CA, USA) at 37°C
followed by three washes in ECS. DRGs were then mechan-
ically dissociated with a set of flame-polished Pasteur pi-
pettes. Dissociated cells were placed on glass coverslips at
room temperature and patch clamp recording was per-
formed within 2–12 h.
Neuronal excitability was examined with long suprathres-
hold current pulse (1 s). The amount of injecting current
(100–500 pA) was individually determined for each neuron
by repeated injections that evoke multiple action potentials.
The TRPV1-positive neurons were selected by observing
immediate inward current when capsaicin was applied.
Once an inward current was induced after puffing capsa-
icin, we recognized this neuron as a TRPV1-positive one.
To compare the effect of single application of capsaicin on
neuronal excitability, the number of action potential was
normalized to that before capsaicin treatment for each
neuron. The ratio of action potential frequency was calcu-
lated from the number of action potential after 5 min wash-
out versus that before capsaicin treatment for each neuron.
Normal ECS contained following: 150 mM NaCl, 5 mM
KCl, 2.5 mM CaCl2, 1 mM MgCl2, 10 mM HEPES and
10 mM glucose, then adjusted to pH 7.4 with NaOH. To
prepare ECS containing 0 mM Ca2+, 2.5 mM CaCl2 was
replaced by 2.5 mM MgCl2. Electrodes had a resistance of
2–4 MΩ when filled with the pipette solution, which con-
tained the following: 140 mM KCl, 1 mM MgCl2, 2.5 mM
CaCl2, 5 mM EGTA, 10 mM HEPES, 2 mM Na-ATP and
0.3 mM Na-GTP, then adjusted to pH 7.3 [55]. Whole-cell
recordings were performed if recorded neurons matched
following criteria: small-diameter DRG neuron with < 30 pF
capacitance, 1 GΩ seal resistance before “breakthrough”
with additional suction and 400 MΩ input resistance in
whole-cell mode. Once whole-cell access was obtained, the
current clamp mode was switched after 5 min balance.
Data were collected using an EPC-9 patch-clamp amplifier
and the Pulse software (version 8.31; HEKA Elektronik).
Action potential parameters were analyzed with MATLAB
program.
Statistical analysis
Statistic analyses were performed using Graphpad Prism
software (Graphpad software). Comparison of values be-
tween two groups was performed by Student’s pair t test or
unpaired t test. Difference for behavior data were compared
with two way ANOVA followed by post hoc test. Differencewas considered to reach statistical significance when p <
0.05. Levels of significance are indicated by the number of
p value, e.g., *, 0.01 < p < 0.05; **, 0.001 < p < 0.01; ***, p <
0.001. Data are present as mean ± SEM.
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